Search

everythinglearnresearchcommunity

for

Search:↓

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

New regenerative therapies show promise for treating hair loss.

Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.

Ginseng and its compounds may help hair growth and prevent hair loss, but more human trials are needed to confirm this.

Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.

Coumarin derivatives show promise as anti-estrogenic agents for treating breast cancer, with some in clinical trials.

New male hormonal contraceptives show promise but need more research on long-term effects and funding for larger trials.

PRP is safe but not more effective than a placebo for treating mild to moderate erectile dysfunction.

The document concludes that a complete skin restoration biomaterial does not yet exist, and more clinical trials are needed to ensure these therapies are safe and effective.

The regenerative medicine industry saw business growth with new partnerships, clinical trials, and financial investments.

The document concludes that research on sulfatase inhibitors should continue due to their potential in treating various diseases, despite some clinical trial failures.

Proxalutamide helps COVID-19 patients get rid of the virus faster and recover quicker.

Low-Level Light Therapy (LLLT) is a safe and effective method for skin rejuvenation, acne treatment, wound healing, body contouring, and hair growth, but more well-designed trials are needed for confirmation.

Setipiprant did not significantly improve hair growth in men with hair loss.

Custom software found that common allergy drugs might have new uses for various conditions and could improve survival in some cancers.

In June 2019, the stem cell research field saw major progress, including new clinical trials, FDA approvals, and industry collaborations.

Hair follicle samples effectively show how well the drug MK-0752 targets and engages with the Notch pathway.

Niosomes are a promising, stable, and cost-effective drug delivery system with potential for improved targeting and safety.

Asia has made significant progress in tissue engineering and regenerative medicine, but wider clinical use requires more development.

Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.

A new compound was effective for imaging prostate cancer in rats.

Finding new uses for existing drugs is promising and can lead to safer, more effective medicines.

Herbal remedies might help with hair loss but need more research for safety and effectiveness.

Ozenoxacin 1% cream is an effective and safe treatment for impetigo in children and adults.

Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.

Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.

Innovative methods are reducing animal testing and improving biomedical research.

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.